cyrilzakka/clinical-trials huggingface dataset:
Chest Physical Therapy on Arterial Blood Gases for Neonates Post Hypoxic Ischemic Encephalopathy

Hypoxic-ischemic encephalopathy (HIE) is a dangerous illness that happens when a newborn's brain does not receive adequate oxygen and blood flow, which can result in serious effects such as cerebral palsy and epilepsy. Infant diagnosed with HIE required ventilator support and subsequently developed pneumonia. They experienced respiratory problems and feeding challenges. Chest Physical Therapy is the best modalities to clear chest and improve ventilation.

The purpose of this study to investigate the effect of chest physical therapy on Arterial Blood Gases for neonates post hypoxic ischemic encephalopathy (HIE) in Neonatal intensive care unit.

Methods: Fifty neonates from both sexes, age from birth to 10 days, post HIE with chest problems were selected from neonatal intensive care unit (NICU) at Minia University hospital, Egypt. They were divided into two equal groups, control group (CG) received traditional medical treatment according to American Academy of Pediatrics (AAP) recommendations and study group (SG) received traditional medical treatment plus Chest Physical Therapy (CPT) modalities in the form of postural drainage, percussion and vibration. The sessions will apply once daily for 6 days/week, each session is about 30 minutes, according to the neonate tolerance till complete clinical cure and discharge from NICU.

the outcome will measure by Timing of Arterial blood gases improvement, Duration required for clinical improvement, Duration of Mechanical ventilation, Duration of Hospitalization.

Eligibility Criteria:
Inclusion Criteria:

* Neonates with chest problems post Hypoxic-ischemic encephalopathy

Exclusion Criteria:

* Neonates with chest problems due to other Causes except post Hypoxic-ischemic encephalopathy.
* unstable medical status
* Neonates with Post-operative s' respiratory problems due to any reasons.
Low-Level Laser Therapy and Injectable Platelet-Rich Fibrin for Thin Gingival Phenotype.

Management of thin gingival phenotype using non-surgical methods (injection of liquid platelet rich fibrin and exposure to low level laser therapy

Thin gingival phenotype can lead to recession and root exposure. Liquid prf can be obtained by centrifugion of blood sample on speed 700 rpm for 3 min, then injection of this liquid in the attached gingiva and muco-gingival junction (3 times with 7 days interval) for the first group. The second group will be injected with I-PRF in the same method in addition to exposure to Low Level Laser therapy (after each injection of I-PRF). This method is expected to increase the thickness of the gingiva.

Eligibility Criteria:
Inclusion Criteria:

* free systimatically good oral hygiene gingival thickness less than 1mm

Exclusion Criteria:

* pregnancy or lactation pereiodontitis periodontal surgery orthodontic ttt tooth mobility,bruxism,crowding,missing or supernumerary teeth smoking
Effectiveness of Trigger Point Dry Needling on Plantar Fasciitis

Plantar fasciitis could lead to pain, disability and impaired balance. Dry needling that targets myofascial trigger points (MTrPs) has been shown to be beneficial in reducing pain, improving range of motion and function in patients with musculoskeletal conditions. Previous systematic review suggested a positive effect of dry needling on improving pain intensity and pain-related disability in patients with plantar heel pain (Llurda-Almuzara et al., 2021). However, the generalisability of the result is limited by small number of trials and heterogenicity in the dry needling application. Also, there is currently no evidence on its effect on dynamic balance and ankle dorsiflexion range of motion. This randomized controlled trial is designed to investigate the effectiveness of dry needling on pain, pain-related disability, dynamic balance and ankle dorsiflexion range of motion in patients with plantar fasciitis.

Twenty participants aged 18 - 65 years with plantar fasciitis will be recruited and randomized to (1) dry needing and stretching exercise group or (2) stretching exercise group, receiving three treatment sessions over three weeks. The primary outcome measure will be numeric pain rating scale (NPRS) and the secondary outcome measures will be Chinese Foot and Ankle Outcome Score (FAOS), modified Star Excursion Balance Test (mSEBT) and weight bearing lunge test (WBLT) measured at baseline and week 4.

Eligibility Criteria:
Inclusion Criteria:

* Age of 18-65 years
* Clinical diagnosis of plantar fasciitis in accordance with the clinical guidelines of the Orthopaedic Section of the American Physical Therapy Association (APTA)
* Pain intensity of a minimum score of 5 on 11-point NPRS
* Presence of trigger points of the gastrocnemius or soleus muscles or both
* History of plantar heel pain for over 1 month

Exclusion Criteria:

* Needle allergy or phobia
* Bleeding disorders or severe vascular disease
* Pregnancy
* Cancer
* Fracture or surgery in the foot region or leg
* Infection
* Dermatological disease in the area of needling
* History of injection therapy in the heel during the previous three months
* Cognitive impairment
* Neurological disorders affecting balance
COVID19 OutcomeS in Myeloma and the Impact of VaCcines

The COVID-19 pandemic has had an outsized impact on individuals with underlying social and medical vulnerability, leading to increased rates of severe disease, hospitalization, and death in these groups. Participants with underlying immune compromise, such as those with multiple myeloma, represent one such group. The advent of vaccines against SARS-CoV-2 has significantly limited morbidity and mortality across all groups, but the effectiveness of vaccination in individuals who are less likely to mount sufficient antibody response is uncertain. For this reason, booster vaccines have been recommended for those with underlying immune compromise. However, several key gaps remain in our understanding of how to best protect these individuals.

There is a dearth of real-world evidence about the effectiveness of vaccination and boosters in patients who are immunocompromised, and very little information specifically about the recently approved mRNA boosters. Additionally, rates of vaccination and booster uptake in the United States remain low. A rapid, decentralized method of ascertaining information related to booster vaccine response and adverse events related to vaccines and COVID-19 infection is critical not only to answer questions about the booster vaccines, but to develop an infrastructure for answering similar questions about future vaccines or other diseases.

The purpose of this project is to implement and establish the feasibility of a decentralized real-world evidence study network for patients with multiple myeloma and to monitor outcomes related to COVID-19 infection in this immunosuppressed population. Subjects with multiple myeloma will be invited to participate. The electronic portal will handle all consenting activities. Participants will be asked to complete specific study procedures electronically, including permission for electronic health record (EHR) data transfer. Participants will be asked to complete electronic questionnaires periodically.

Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of multiple myeloma per the International Myeloma Working Group and currently receiving active treatment for any phase of the disease, including initial therapy, maintenance, or relapsed disease.
* Access to the internet
* An active patient portal (or willingness to activate)
* Willing to electronically sign the study-specific informed consent and authorization form

Exclusion Criteria:

* Non-English speaking
* Lack of internet access
* Cognitive impairment precluding ability to provide informed consent
ADG126, ADG126 in Combination With Anti PD1 Antibody, and ADG126 in Combination With ADG106 in Advanced/Metastatic Solid Tumors

ADG126, ADG126 in Combination with anti-PD1 antibody, and ADG126 in Combination with ADG106 in Patients with Advanced/Metastatic Solid Tumors .

ADG126 is a novel anti-CTLA-4 fully human IgG1 antibody prodrug that is modified with Adagene Safebody technology to control the activation of anti-CTLA4 activity.ADG106 is a fully human ligand-blocking, agonistic anti-CD137 IgG4 mAb which is expected to enhance the activity of activated T cells. The enhanced antitumor efficacy results observed from the preclinical studies of ADG126 in combination with ADG106 or anti-PD-1 provided further support to explore such combinations in clinical settings for better patient responses.

Eligibility Criteria:
Inclusion criteria

1. Adults ≥18 years of age.
2. ECOG performance status 0 or 1.
3. Estimated life expectancy of more than 12 weeks .
4. Patients with advanced or metastatic solid tumors, confirmed by histologically or pathologically documented, who have progressed after all standard therapies, or for whom no further standard therapy exists.
5. At least 1 measurable lesion at baseline according to the definition of RECIST v1.1.
6. Adequate organ function.
7. Meets the additional tumor type requirements as specified in Protocol.

Exclusion Criteria:

1. Treatment with any investigational drug within washout period.
2. Major trauma or major surgery within 4 weeks prior to first dose of study drug(s)
3. History of significant immune-mediated AE.
4. Central nervous system (CNS) disease involvement.
5. Prior organ allograft transplantations or allogeneic peripheral blood stem cell (PBSC)/bone marrow (BM) transplantation
6. Clinically significant cardiac disease.
7. Evidence of active uncontrolled viral, bacterial, or systemic fungal infection.
8. Patients who received:

   1. A COVID-19 vaccine within 7 days of Cycle 1 Day 1.
   2. Live vaccines or live-attenuated vaccines within 28 days prior to Cycle 1 Day 1.
9. Known active infection of HBV/BCV/HIV.
10. Patients requiring systemic treatment with corticosteroids or other immunosuppressive medications (\>10 mg/day prednisone or equivalent).
11. Second primary malignancy not in remission for greater than 3 years.
12. History(within the last 5 years) or risk of autoimmune disease.
13. Pregnant or breastfeeding females.
14. Childbearing potential who does not agree to the use of contraception during the treatment period.
COPD Patient-Powered Research Network

The COPD Patient-Powered Research Network (COPD PPRN) is a patient research registry with the goal of enrolling 75,000 or more COPD patients and those at risk who are willing to share their heath information over several years and participate in research. The COPD PPRN has built an online platform to allow volunteers to enroll electronically, complete surveys, be contacted about studies they qualify for and become connected to COPD resources. The goal of the registry is to speed research to find better treatments for COPD and ultimately a cure.


Eligibility Criteria:
Inclusion Criteria:

* 18 years or older that says yes to one of the following:
* COPD diagnosis
* Current or former smoker
* Family history of respiratory disease
* Symptomatic of respiratory disease

Exclusion Criteria:

* Non-English speaking
Study of Intramuscular Injections of ABBV-950 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Spasticity

Spasticity is often observed as muscle tightness and stiffness in the upper and/or lower limbs. Upper limb spasticity can interfere with joint movement and its severity can range from mild to severe. Common causes of spasticity include cerebral palsy, traumatic brain injury, multiple sclerosis, spinal cord injury, and stroke. This study will assess how safe and effective ABBV-950 is in treating upper limb spasticity in adult post-stroke participants. Adverse events and change in symptoms will be assessed.

ABBV-950 in an investigational drug being developed for treating spasticity. This study is conducted in 2 parts. In Part 1, participants are assigned to receive different doses of ABBV-950 or placebo. There is 1 in 4 chance that participants will be assigned to receive placebo. In Part 2, participants will be randomly assigned to receive BOTOX, ABBV-950, or placebo. There is 1 in 5 chance for participants to receive placebo. Approximately 297 adult post-stroke participants with upper limb spasticity will be enrolled at approximately 50 sites in the United States.

In Part 1, participants will receive intramuscular (IM) injections of ABBV-950 or placebo on Day 1. In Part 2, participants will receive IM injections of BOTOX, ABBV-950, or placebo on Day 1. All participants will be followed for 24 weeks.

There may be higher treatment burden for participants in this trial compared to the standard of care. Participants will attend regular clinic visits during the study. The effect of the treatment will be checked by medical assessments, checking for side effects and completing questionnaires.


Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of upper limb spasticity due to stroke, with most recent stroke occurring at least 12 weeks prior to the Screening visit.
* Modified Ashworth Scale-Bohannon (MAS-B) score of \>= 3 in the wrist flexors, and a score of \>= 1+ in the finger flexors and MAS-B score of \>= 2 elbow flexors at both Screening and Visit 2 (Baseline).

Exclusion Criteria:

* Additional strokes in the 12 weeks preceding the most recent stroke and in the opinion of the investigator, is not at significant risk of experiencing another stroke during the study period.
* Spasticity in the contralateral upper limb that requires treatment.
* Presence of fixed contractures in muscles of wrist, elbow, fingers.
* Botulinum toxin treatment of any serotype in the 20 weeks prior to Day for upper limb spasticity and in the 12 weeks prior to Day 1 for any indication other than upper limb spasticity.
* Previous surgical intervention, nerve block, or muscle block for the treatment of spasticity in the study limb in the last 12 months.
* Injection of corticosteroids or anesthetics in the study limb within 12 weeks.
* Casting of the upper limbs within 12 weeks.
* Diagnosis of myasthenia gravis, Eaton-Lambert syndrome, and/or amyotrophic lateral sclerosis.
The Effect of Physical Therapy Modalities and Kinesio Taping in Patients With Knee Osteoarthritis

Osteoarthritis (OA) is the most common degenerative joint disease with pathological structural and functional disorders all over the world. 27 million patients diagnosed with osteoarthritis in the USA alone.(1-2)

Osteoarthritis (OA) is the most common degenerative joint disease with pathological structural and functional disorders all over the world. 27 million patients diagnosed with osteoarthritis in the USA alone.(1-2) The primary risk factor for OA is age however ; It is a multifactorial disease, including injury and genetic mutations.(3-6) The knee is the most commonly involved joint in OA. In the United States, about 14 million people is presumed to have symptomatic knee osteoarthritis. Typical OA manifests as joint pain which is exacerbated by activity and relieved by rest. In advanced stage, pain at rest and at night and morning stiffness lasting no more than 20-30 minutes can be seen. (2) The diagnosis is based on a detailed anamnesis, a complete physical examination, and diagnostic imaging. Imaging findings include joint space narrowing, osteophytes, pseudocyst and subchondral sclerosis in the subchondral bone.(9) Pharmacological and non-pharmacological treatments are applied. Exercise, conventional physical therapy ( hotpack, therapeutic ultrasound, tens) and kinesioband are some of the non-pharmacological treatments.

Eligibility Criteria:
Inclusion Criteria:

over 50 ages Stage 2-3 osteoarthritis according to Kellgren Lawrence lectures

Exclusion Criteria:

Presence of acute infection The patient has a history of knee surgery Presence of rheumatological disease History of malignancy Major knee trauma Presence of crystal arthropathy Presence of acute trauma/fracture History of avascular necrosis The presence of contracture in the knee Using analgesic or anti-inflammatory drugs in the last 1 week Using oral or intramuscular corticosteroids in the last 3 months Intra-articular injection of the knee in the last 6 months Receiving physical therapy modalities from the knee area in the last 1 year Diseases such as dementia that may cause loss of cognitive functions
SUPARTZ Versus Placebo in Osteoarthritis of the Shoulder

This clinical trial is to determine the safety and effectiveness of three injections of SUPARTZ (sodium hyaluronate) compared with phosphate buffered saline (PBS) for the treatment of glenohumeral osteoarthritis of the shoulder. The trial contains two phases. Phase I is 26 weeks, double blinded, and subjects are randomized to either SUPARTZ or PBS treatment. Phase II is 26 weeks (total 52 weeks) and open-label so all subjects will receive SUPARTZ injections only.

Phase 3 Study: Multi-center, randomized, double blinded, two phase study to determine the safety and efficacy of 3 injections of SUPARTZ for Osteoarthritis of the Shoulder

Eligibility Criteria:
Inclusion Criteria:

* Glenohumeral Osteoarthritis (OA) confirmed by radiograph
* Limitation of shoulder motion in at least one direction
* Retained active range of motion of at least 30% in all directions

Exclusion Criteria:

* Full thickness rotator cuff tear or rotator cuff tendinopathy
* Frozen shoulder
* Female who is pregnant or lactating
Correlation Study of Lipid Metabolites as Markers of Hepatocellular Carcinoma

As one of the common malignant tumors in China, primary liver cancer, whose incidence rate and mortality rate are always in the top five, is seriously threatening the health of people. Therefore, early diagnosis and treatment of primary liver cancer are of great significance. In recent years, the incidence of primary liver cancer, which is caused by hepatic steatosis or metabolic dysfunction-related liver disease, is increasing year by year, and it has become one of the fastest rising causes in some developed countries. More and more studies have also confirmed that the levels of different kinds of lipids and their metabolites are correlated with the development of hepatocellular carcinoma. In this study, the researchers performed qualitative and quantitative analyses of various common lipid metabolites in plasma and liver cancer tissues of hepatic resection patients with hepatocellular carcinoma, collected tumor-related pathological data from the patients, and investigated the correlation between the lipid metabolites and the development of hepatocellular carcinoma, in order to provide a new idea for the early diagnosis and treatment of primary hepatocellular carcinoma, as well as for screening of hepatocellular carcinoma markers.


Eligibility Criteria:
Inclusion Criteria:

* Patients aged 18-80 years old undergoing hepatic resection for hepatocellular carcinoma (diagnostic criteria for hepatocellular carcinoma refer to the guidelines for the diagnosis and treatment of primary hepatocellular carcinoma).
* Voluntary signing of informed consent

Exclusion Criteria:

* In the judgment of the investigator, they are not suitable to participate in this study.
* Patients with hepatic malignant tumors with invasion of the main portal vein and its first-order branches, the common hepatic duct and its first-order branches, the main hepatic vein and the inferior vena cava, or extrahepatic metastases.
* Surgery with biliary tract exploration or reconstruction in the presence of biliary obstruction.
* Surgery combined with splenectomy or splenic artery ligation
* Preoperative combination of cardiac, pulmonary, renal and other organs with major underlying diseases.
Thermal Suit With Forced-air Warming in Breast Cancer Surgery

The aim of this clinical investigation is to prove that the thermal suit with forced-air warming is more effective to prevent inadvertent intraoperative hypothermia than conventional warming methods. The study group will have the thermal suit from arriving to the hospital until to the ward after surgery. In the operating theatre forced-air warming device will be connected to the trouser legs of the thermal suit and the device will be turned on during surgery. The control group will have normal hospital clothes. Intraoperative warming will be managed with the warming mattress and a forced-air warming blanket. The primary endpoint is core temperature after arriving to the post-anaesthesia care unit.


Eligibility Criteria:
Inclusion Criteria:

* primary breast cancer surgery
* unilateral resection or mastectomy with or without axillar lymphadenectomy
* body mass index 25-40

Exclusion Criteria:

* ASA \> III
* decreased mental status
* inadequate Finnish language skills
* other than general anaesthesia
Antibiotics Versus Therapeutic Ultrasound for Sinusitis

Question: Is the effect of therapeutic ultrasound equally effective to antibiotic for treatment of sinusitis? Design: A randomized clinical trial with concealed allocation, self-assessment by the subjects and intention-to-treat analysis.

Subjects (n=48) with clinically diagnosed acute bacterial rhinosinusitis (ABRS)will included. The antibiotic group will receive amoxicillin (500 mg) 3 times per day for 10 days. The ultrasound group will receive therapeutic ultrasound over sinuses at 1.0 W/cm2 in continuous mode for 10 minutes once a day for 4 consecutive days. Improvement of symptoms (pain and congestion; numeric rating scale; 0-10) from day 1 to days 4 and 21 will be recorded. Relapses, side-effects and satisfaction with treatment will be assessed at one-year follow-up.

Eligibility Criteria:
Inclusion Criteria:

* Pain when bending forward, headache, pain in the teeth, purulent nasal secretion, "double worsening" and white blood cell count (WBC).
* Patients eligible for the study had to meet one of the first three criteria (pain when bending forward, headache, pain in the teeth) and all of the other indicators (purulent nasal secretion, double worsening, a left handed displacement of lymphocytes and a right handed displacement of granulocytes on the WBC as indication of bacterial infection).
* Subjects over 15 years of age were included.

Exclusion Criteria:

* Subjects with any kind of antibiotic or allergic treatment within the last three weeks.
* Antibiotic intolerance.
* Pregnant women.